Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternative Sunitinib Scheduling in mRCC
NCT02060370Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2014
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in metastatic renal cell carcinoma (mRCC), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2014; status: completed.
02
Drugs
sunitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02060370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02060370.